Document is current

Article History

Received: 17 May 2024

Accepted: 9 July 2024

First Online: 24 July 2024

Declarations

:

: A patent has been filed for the nordicPRO-C12 ELISA. M.A.K. and N.W. are employed at Nordic Bioscience A/S, a biotech company involved in the discovery and development of blood-based biomarkers. M.C.B., J.T.U, A.H. and T.R.C. have no conflict of interest to declare. M.A.K. and N.W. own stock in Nordic Bioscience A/S.

: The production of monoclonal antibodies in mice was authorized by the Danish National Authority (The Animal Experiments Inspectorate) under approval No. 2018-15-0201-01574. All animal procedures adhered to the guidelines for animal welfare. The research followed the ARRIVE guidelines (Animal Research: Reporting of in Vivo Experiments) to ensure comprehensive and transparent reporting of experimental methods. serum samples were obtained following patients’ informed consent, which was sanctioned by the Russian Oncological Research Centre n.a. Blokhin RAMS (PG-ONC 2033/1) (Moscow, Russia) and the Western Institutional Review Board, Inc. (Puyallup, WA, USA) (WIRB®Protocol #20161665). All investigations were conducted in accordance with the Helsinki Declaration.